# @time on YouTube

- **Type:** Video
- **Original URL:** https://youtube.com/watch?v=_Dd9co7rrHQ
- **Gondola URL:** https://gondola.cc/posts/70317030-time-youtube
- **Thumbnail:** https://img.gondola.cc/tr:w-,h-,fo-auto/postThumbnails/d9332c478c.jpg
- **Posted:** 2026-09-13T17:00:06.000+00:00
- **Account Owner:** TIME (@TIME) — https://gondola.cc/TIME

## Caption

When there are breakthrough technologies like xenotransplants, or novel cancer therapies, they’re transformative for diseases and conditions once thought incurable—but they can only save lives if the people that need them can access them. On September 10, TIME hosted the third annual TIME100 Health Leadership Forum in New York City, bringing together the TIME and TIME100 Health communities to discuss equity, longevity, and solution-driven care. The evening featured five expert panels, including The Access Gap: Expanding Pathways to Life-Saving Care. Moderated by TIME senior health correspondent Alice Park, the panel invited faculty physicians specializing in cell therapies from Oregon Health & Science University and Penn Medicine to take part in conversation with Amy Ronneberg, chief executive officer of NMDP, a global nonprofit connecting patients with lifesaving cell therapies and transplants. NMDP is a sponsor of the 2026 TIME100 Health Leadership Forum.

While modern science has solved some access issues, others still remain. “If we go back six years, the biggest barrier was the fact that there were not donors to match,” says Ronneberg. “As more patients have a donor, we now are facing issues around referral. Thousands of patients are not getting referred to transplant centers in a timely manner, those that are oftentimes are facing major barriers from a financial perspective.”

Read more: https://time.com/collection/time100-leadership-forums/2026/the-access-gap-expanding-pathways-to-life-saving-care/

Subscribe to TIME’s YouTube channel ►► http://ti.me/subscribe-time
Subscribe to TIME: https://ti.me/3E3UCqt
Get the day’s top headlines to your inbox, curated by TIME editors: https://ti.me/48dFNwQ
Follow us:
X (Twitter): https://ti.me/3xTVwSk
Facebook: https://ti.me/3xWI2Fg 
Instagram: https://ti.me/3dO9Rcc

0:00 Why Breakthrough Treatments Still Face Access Barriers
1:14 How Donor Matching Has Changed for Transplant Patients
2:44 Referral Delays, Cost & Health Equity
3:13 Why Patients Miss Advanced Cancer Therapies
5:25 What Is CAR T-Cell Therapy?
7:21 How Geography Limits Access to Specialty Care
8:24 Why Patients Should Help Shape Treatment Systems
9:50 Education, Travel Costs & Navigating Cancer Care
11:11 Building Access Into Breakthrough Therapies
13:11 Bringing CAR T-Cell Therapy Into Community Care
14:26 How CAR T-Cell Treatment Is Collected & Manufactured
15:52 Expanding Academic Expertise Into Community Centers
17:16 Training Community Hospitals to Deliver Advanced Care
18:48 How NMDP Is Expanding Access to Cell Therapy
20:41 CAR T-Cell Safety, Risks & Recent Trial Deaths
22:30 The Next Frontier: CAR T-Cell Therapy for Autoimmune Disease
24:13 Closing Thoughts on Expanding Access to Specialty Care

#HealthEquity #CancerCare

## Stats

- **Views:** 1,929
- **Likes:** 9
- **Shares:** 0
- **Comments:** 1

## Tags

healthequity, cancercare

---
Copyright (c) Gondola